



DEHESA DERMATOLOGY

Dehesa Dermatology

978 N. Temperance Ave. Clovis CA 93611

(P) 559.951.9000 (F) 559. 234.6334

<https://dehesadermatology.com>

SKYRIZI® (RISANKIZUMAB-RZAA) INJECTION / INFUSION ORDER

Patient Information

Patient Name: _____

Address: _____

DOB: _____

Phone: _____

Patient Height: _____

Patient Weight (kg): _____

Diagnosis: _____

ICD-10 Code: _____

Attach:

- ☐ Patient demographics
- ☐ Copy (front & back) of insurance card(s)
- ☐ Most recent clinical notes

Required Screening / Baseline Evaluation (Results must accompany order)

- ☐ Tuberculosis Screening (QuantiFERON-TB Gold or TST)
- ☐ Hepatitis B Surface Antigen (HBsAg)
- ☐ Hepatitis B Core Antibody (Total Anti-HBc)
- ☐ Hepatitis C Screening
- ☐ Baseline CBC
- ☐ Baseline CMP

Medication Order

- ☐ SKYRIZI® (Risankizumab-rzaa) 150 mg subcutaneous injection

Dosing Regimen:

- ☐ 150 mg subcutaneous at Week 0
- ☐ 150 mg subcutaneous at Week 4
- ☐ Then every 12 weeks thereafter
- ☐ Other: _____



DEHESA DERMATOLOGY

Dehesa Dermatology

978 N. Temperance Ave. Clovis CA 93611

(P) 559.951.9000 (F) 559. 234.6334

<https://dehesadermatology.com>

IV Induction:

☐ SKYRIZI® _____ mg IV at Week 0

☐ SKYRIZI® _____ mg IV at Week 4

☐ SKYRIZI® _____ mg IV at Week 8

Maintenance:

☐ 180 mg subcutaneous every 8 weeks

☐ 360 mg subcutaneous every 8 weeks

☐ Other: _____

Pre-Medications

☐ None

☐ Acetaminophen 650 mg PO once

☐ Diphenhydramine 25–50 mg PO or IV once

☐ Methylprednisolone _____ mg IV once

☐ Other: _____

PRN / Emergency Medications

Administer per reaction protocol if clinically indicated:

☐ Diphenhydramine 25–50 mg PO or IV PRN

☐ Methylprednisolone 125 mg IV PRN

☐ Famotidine 20 mg IV PRN

☐ Epinephrine 0.3 mg IM PRN anaphylaxis

☐ Albuterol 2.5 mg nebulized PRN bronchospasm

☐ Normal Saline IV bolus PRN hypotension

Additional Instructions

Ordering Physician:

Printed Name: _____

Signature: _____ Date: _____

Contact Person: _____

Phone: _____ Fax: _____

FAX ORDER TO 559.234.633